A novel mechanism of rifamycin resistance in Mycobacterium abscessus mediated by a putative helicase

由假定的解旋酶介导的脓肿分枝杆菌利福霉素耐药性的新机制

基本信息

  • 批准号:
    10408177
  • 负责人:
  • 金额:
    $ 18.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-20 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary: Mycobacterium abscessus (Mab) is a rapidly growing NTM causing skin and soft tissue infections as well as pulmonary infections in patients with chronic lung damage. Mab stands apart as one of the most antibiotic resistant microbial species, making its infections incredibly difficult to treat. Particularly striking is its resistance to rifampicin (RIF), a frontline drug for many mycobacterial infections including tuberculosis. RIF inhibits global RNA synthesis by binding to the b-subunit of bacterial RNA polymerase; additionally it is also known to inhibit replication initiation due to an inhibition of dnaA expression. The intrinsic RIF resistance in Mab has so far been attributed to the presence of an ADP-ribosyltransferase (Arr) activity that ribosylates RIF leading to its inactivation. However, we have recently identified an additional determinant, MAB_3189c - a putative helicase, that confers high levels of RIF resistance in Mab. MAB_3189c expression is RIF inducible and is likely regulated by a RIF-associated element (RAE) dependent transcription factor. In this project we will determine the regulation and function of Mab3189c in RIF resistance. In Aim 1 we will investigate if Mab3189c mediates RIF resistance by either directly protecting RNAP against the action of RIF thereby enabling global RNA synthesis to continue, or by alleviating RIF-sensitive replication initiation at oriM thereby enabling growth in the presence of RIF. In Aim 2 we propose to identify the regulatory protein required for RAE-dependent induction of MAB_3189c. The findings will provide a platform for a long-term study to gain insights into Mab3189c dependent RIF resistance in Mab, and design of new strategies to treat Mab infections.
项目摘要: 分枝杆菌(MAB)是一种快速生长的NTM,引起皮肤和软组织感染 以及慢性肺损伤患者的肺部感染。 mab是最多的人之一 抗生素耐药物种,使其感染难以治疗。特别是惊人的是 它对利福平(RIF)的耐药性,这是一种用于许多分枝杆菌感染的前线药物,包括结核病。 RIF通过与细菌RNA聚合酶的B-亚基结合来抑制全局RNA合成;另外 还已知由于DNAA表达抑制复制起始。内在的RIF 迄今为止,MAB中的抗性归因于ADP-核糖基转移酶(ARR)活性的存在 核糖基rif导致其失活。但是,我们最近确定了 决定符,mab_3189c-一种推定的解旋酶,它赋予了MAB中较高的RIF耐药性。 MAB_3189C的表达是rif诱导的,很可能由RIF相关元件(RAE)调节 依赖转录因子。在这个项目中,我们将确定MAB3189C的调节和功能 在RIF抗性中。在AIM 1中,我们将调查MAB3189C是否直接介导了RIF的耐药性 保护RNAP免受RIF的作用,从而使全球RNA合成继续或通过 减轻Orim的RIF敏感复制启动,从而在RIF的存在下实现增长。目标 2我们建议确定MAB_3189C RAE依赖性诱导所需的调节蛋白。这 调查结果将为长期研究提供一个平台,以洞悉MAB3189C依赖RIF MAB的耐药性,以及治疗MAB感染的新策略的设计。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mycobacterium abscessus HelR interacts with RNA polymerase to confer intrinsic rifamycin resistance.
  • DOI:
    10.1016/j.molcel.2022.06.034
  • 发表时间:
    2022-09-01
  • 期刊:
  • 影响因子:
    16
  • 作者:
    Hurst-Hess, Kelley R.;Saxena, Aavrati;Rudra, Paulami;Yang, Yong;Ghosh, Pallavi
  • 通讯作者:
    Ghosh, Pallavi
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Pallavi Ghosh其他文献

Pallavi Ghosh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Pallavi Ghosh', 18)}}的其他基金

A novel mechanism of rifamycin resistance in Mycobacterium abscessus mediated by a putative helicase
由假定的解旋酶介导的脓肿分枝杆菌利福霉素耐药性的新机制
  • 批准号:
    10302960
  • 财政年份:
    2021
  • 资助金额:
    $ 18.91万
  • 项目类别:
Role of ribosome modulating proteins in conferring Mycobacterium abscessus antibiotic resistance
核糖体调节蛋白在赋予脓肿分枝杆菌抗生素耐药性中的作用
  • 批准号:
    10461966
  • 财政年份:
    2020
  • 资助金额:
    $ 18.91万
  • 项目类别:
Role of ribosome modulating proteins in conferring Mycobacterium abscessus antibiotic resistance
核糖体调节蛋白在赋予脓肿分枝杆菌抗生素耐药性中的作用
  • 批准号:
    10267728
  • 财政年份:
    2020
  • 资助金额:
    $ 18.91万
  • 项目类别:
Role of ribosome modulating proteins in conferring Mycobacterium abscessus antibiotic resistance
核糖体调节蛋白在赋予脓肿分枝杆菌抗生素耐药性中的作用
  • 批准号:
    10684744
  • 财政年份:
    2020
  • 资助金额:
    $ 18.91万
  • 项目类别:
Role of ribosome modulating proteins in conferring Mycobacterium abscessus antibiotic resistance
核糖体调节蛋白在赋予脓肿分枝杆菌抗生素耐药性中的作用
  • 批准号:
    10094343
  • 财政年份:
    2020
  • 资助金额:
    $ 18.91万
  • 项目类别:
Elucidation of a novel mechanism of macrolide resistance in Mycobacterium abscessus
阐明脓肿分枝杆菌大环内酯类耐药的新机制
  • 批准号:
    9804856
  • 财政年份:
    2019
  • 资助金额:
    $ 18.91万
  • 项目类别:
Identification of novel DNA repair mechanisms in Mycobacterium tuberculosis
结核分枝杆菌新型 DNA 修复机制的鉴定
  • 批准号:
    8113596
  • 财政年份:
    2011
  • 资助金额:
    $ 18.91万
  • 项目类别:
Identification of novel DNA repair mechanisms in Mycobacterium tuberculosis
结核分枝杆菌新型 DNA 修复机制的鉴定
  • 批准号:
    8223133
  • 财政年份:
    2011
  • 资助金额:
    $ 18.91万
  • 项目类别:

相似海外基金

Investigating microbiota of the gut-brain axis and the impact of cocaine
研究肠脑轴的微生物群和可卡因的影响
  • 批准号:
    10625082
  • 财政年份:
    2023
  • 资助金额:
    $ 18.91万
  • 项目类别:
Integrative Multidisciplinary Discovery Platform to Unlock Marine Natural Products Therapeutic Opportunities
综合多学科发现平台释放海洋天然产品治疗机会
  • 批准号:
    10413304
  • 财政年份:
    2022
  • 资助金额:
    $ 18.91万
  • 项目类别:
Functional consequences of bacterial-fungal dysbiosis in E/VLBW infants
E/VLBW 婴儿细菌-真菌失调的功能后果
  • 批准号:
    10373520
  • 财政年份:
    2022
  • 资助金额:
    $ 18.91万
  • 项目类别:
Impact of Saccharibacteria and their bacterial hosts in Periodontal and Inflammatory Diseases
糖杆菌及其细菌宿主对牙周病和炎症性疾病的影响
  • 批准号:
    10541194
  • 财政年份:
    2022
  • 资助金额:
    $ 18.91万
  • 项目类别:
A machine learning-based screen of marine natural products to identify new leads for the treatment of Acanthamoeba eye infection
基于机器学习的海洋天然产品筛选,以确定治疗棘阿米巴眼部感染的新线索
  • 批准号:
    10669249
  • 财政年份:
    2022
  • 资助金额:
    $ 18.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了